UnknownPhase 4NCT01501149
Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ
Studying Extranodal nasal NK/T cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mingzhi Zhang
- Principal Investigator
- Mingzhi Zhang, Pro，DrThe First Affiliated Hospital of Zhengzhou University
- Intervention
- DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)(drug)
- Enrollment
- 80 target
- Eligibility
- 14-70 years · All sexes
- Timeline
- 2011 – 2019
Study locations (1)
- Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Collaborators
Second Hospital of Shanxi Medical University · Shanxi Province Cancer Hospital · Wuhan University · Wuhan TongJi Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Qingdao University · Cancer Hospital of Guizhou Province · Xinyang Central Hospital · The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01501149 on ClinicalTrials.govOther trials for Extranodal nasal NK/T cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07380984PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06966154A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLFudan University
- RECRUITINGPHASE2NCT07000617A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell LymphomaPeking University Cancer Hospital & Institute
- RECRUITINGPHASE1NCT06732492RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ENROLLING BY INVITATIONNCT07450040Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell LymphomaEye & ENT Hospital of Fudan University
- RECRUITINGPHASE1, PHASE2NCT06559553"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCLMingzhi Zhang
- RECRUITINGPHASE2NCT06824883Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaPeking Union Medical College Hospital
- RECRUITINGPHASE1, PHASE2NCT06376721Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaBeijing Tongren Hospital